B+
Bull case
25%
Probability
Target price
$145.00
+30.5% vs current
MNPR
Monopar TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$115.00
+3.5% vs current
B-
Bear case
25%
Probability
Target price
$75.00
-32.5% vs current
AI sentiment snapshot
Latest data as of 2026-07-19
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+50.6
Score
AI commentary
Recent-news coverage and social context are unavailable or insufficient, so sentiment scores are treated as neutral/no-signal rather than positive evidence. Post-earnings price reaction and analyst revision data are also unavailable. The primary-source evidence supports a monitoring thesis centered on NDA status, not a high-conviction directional call.
RankAlpha Sentiment Codex - 2026-07-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-17eventALXN1840 NDA submission and regulatory-status updateHigh impact
Management said the NDA for ALXN1840 in Wilson disease was on track for mid-2026, with commercial-readiness work underway. Submission status and FDA timing are not confirmed in the packet. [#PR-EARNINGS-2026-05-15] [#SEC-8K-2026-05-14]
2027-07-19catalystPotential Wilson disease commercialization pathHigh impact
Positive Phase 3 FoCus analyses and reported cash runway through at least December 31, 2027 support continued regulatory and potential commercial activity, but approval, launch execution, and adoption remain uncertain. [#PR-EARNINGS-2026-05-15]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-19 • Updated nightlySource: Internal modelMethodology